Key result
Isolated low LAD V15Gy during NSCLC radiation is linked to ~66% lower MACE risk.
Why the study?
Mean heart dose and LAD coronary artery volume receiving 15 Gy both increase MACE risk in NSCLC, but the discordance between them and its effect on MACE risk remained uncharacterized.
Does low LAD V15Gy reduce the risk of MACE in patients with locally advanced NSCLC treated with radiation therapy compared to high LAD V15Gy?
Cohort (n=701)
Does low LAD V15Gy reduce the risk of MACE in patients with locally advanced NSCLC treated with radiation therapy compared to high LAD V15Gy?
Effect estimate: SHR 0.34 (95% CI 0.13-0.93)
p-value: p=0.036
Mean heart dose is an inadequate surrogate for LAD dose, and isolated low LAD V15Gy significantly reduces the risk of MACE in patients with locally advanced NSCLC after radiation therapy.
Mean heart dose may inadequately surrogate LAD exposure for MACE risk in NSCLC RT; leaves open prospective validation of LAD-specific constraints.
PurposeMean heart dose (MHD) over 10 Gy and left anterior descending (LAD) coronary artery volume (V) receiving 15 Gy (V15Gy) greater than 10% can significantly increase the risk of major adverse cardiac events (MACE) in patients with non-small cell lung cancer (NSCLC). We sought to characterize the discordance between MHD and LAD dose and the association of this classification on the risk of MACE after radiation therapy.Methods and MaterialsThe coefficient of determination for MHD and LAD V15Gy was calculated in this retrospective analysis of 701 patients with locally advanced NSCLC treated with radiation therapy. Four groups were defined on the basis of high or low MHD (≥10 Gy vs <10 Gy) and LAD V15Gy (≥10% vs <10%). MACE (unstable angina, heart failure, myocardial infarction, coronary revascularization, and cardiac death) cumulative incidence was estimated, and Fine and Gray regressions were performed.ResultsThe proportion of variance in LAD V15Gy predictable from MHD was only 54.5% (R2 = 0.545). There was discordance (where MHD was high [≥10 Gy] and LAD low [V15Gy < 10%], or vice versa) in 23.1% of patients (n = 162). Two-year MACE estimates were 4.2% (MHDhigh/LADlow), 7.6% (MHDhigh/LADhigh), 1.8% (MHDlow/LADlow), and 13.0% (MHDlow/LADhigh). Adjusting for pre-existing coronary heart disease and other prognostic factors, MHDhigh/LADlow (subdistribution hazard ratio [SHR], 0.34; 95% CI, 0.13-0.93; P = .036) and MHDlow/LADlow (SHR, 0.24; 95% CI, 0.10-0.53; P < .001) were associated with a significantly reduced risk of MACE.ConclusionsMHD is insufficient to predict LAD V15Gy with confidence. When MHD and LAD V15Gy dose exposure is discordant, isolated low LAD V15Gy significantly reduces the risk of MACE in patients with locally advanced NSCLC after radiation therapy, suggesting that the validity of whole heart metrics for optimally predicting cardiac events should be reassessed. Mean heart dose (MHD) over 10 Gy and left anterior descending (LAD) coronary artery volume (V) receiving 15 Gy (V15Gy) greater than 10% can significantly increase the risk of major adverse cardiac events (MACE) in patients with non-small cell lung cancer (NSCLC). We sought to characterize the discordance between MHD and LAD dose and the association of this classification on the risk of MACE after radiation therapy. The coefficient of determination for MHD and LAD V15Gy was calculated in this retrospective analysis of 701 patients with locally advanced NSCLC treated with radiation therapy. Four groups were defined on the basis of high or low MHD (≥10 Gy vs <10 Gy) and LAD V15Gy (≥10% vs <10%). MACE (unstable angina, heart failure, myocardial infarction, coronary revascularization, and cardiac death) cumulative incidence was estimated, and Fine and Gray regressions were performed. The proportion of variance in LAD V15Gy predictable from MHD was only 54.5% (R2 = 0.545). There was discordance (where MHD was high [≥10 Gy] and LAD low [V15Gy < 10%], or vice versa) in 23.1% of patients (n = 162). Two-year MACE estimates were 4.2% (MHDhigh/LADlow), 7.6% (MHDhigh/LADhigh), 1.8% (MHDlow/LADlow), and 13.0% (MHDlow/LADhigh). Adjusting for pre-existing coronary heart disease and other prognostic factors, MHDhigh/LADlow (subdistribution hazard ratio [SHR], 0.34; 95% CI, 0.13-0.93; P = .036) and MHDlow/LADlow (SHR, 0.24; 95% CI, 0.10-0.53; P < .001) were associated with a significantly reduced risk of MACE. MHD is insufficient to predict LAD V15Gy with confidence. When MHD and LAD V15Gy dose exposure is discordant, isolated low LAD V15Gy significantly reduces the risk of MACE in patients with locally advanced NSCLC after radiation therapy, suggesting that the validity of whole heart metrics for optimally predicting cardiac events should be reassessed.
No takes yet. Share an insight, caveat, or question.
Atkins et al. (2021) conducted a cohort in Locally advanced non-small cell lung cancer (NSCLC) (n=701). Low LAD V15Gy (<10%) with high mean heart dose (≥10 Gy) vs. High LAD V15Gy (≥10%) was evaluated on Major adverse cardiac events (unstable angina, heart failure, myocardial infarction, coronary revascularization, and cardiac death) (SHR 0.34, 95% CI 0.13-0.93, p=0.036). In patients with NSCLC treated with radiation therapy, isolated low LAD V15Gy despite high mean heart dose significantly reduced the risk of MACE (SHR 0.34; 95% CI 0.13-0.93; P=0.036).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: